Mangoceuticals (Mangoceuticals) Net Income From Continuing Operations : $-9.02 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Mangoceuticals Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Mangoceuticals's net income from continuing operations for the three months ended in Mar. 2024 was $-2.37 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was $-9.02 Mil.

Mangoceuticals Net Income From Continuing Operations Historical Data

The historical data trend for Mangoceuticals's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mangoceuticals Net Income From Continuing Operations Chart

Mangoceuticals Annual Data

Trend

Dec21

Dec22

Dec23

Net Income From Continuing Operations

-2.00

-9.21

Mangoceuticals Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial					-2.56	-2.28	-1.80	-2.57	-2.37

Mangoceuticals Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.02 Mil.

Mangoceuticals (Mangoceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Mangoceuticals Inc (NAS:MGRX) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

15110 N. Dallas Parkway, Suite 600, Dallas, TX, USA, 75248

Website

https://www.mangoceuticals.com

Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The platform provide access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED product.

Executives

Amanda Elizabeth Hammer	officer: Chief Operating Officer	5128 GADSDEN AVENUE, KELLER TX 76244
Jacob D. Cohen	director, 10 percent owner, officer: CEO	2101 GLENDALE DRIVE, PLANO TX 75023
Tiger Cub Trust	10 percent owner	19 RYDDINGTON PL, DALLAS TX 75230
Kenny Myers	director	5101 ADDISON CIRCLE,, UNIT 401,, ADDISON TX 75001
Lorraine Pamela D'alessio	director	8200 WILSHIRE BLVD, BEVERLY HILLS, CALIFORNIA CA 90211
Eugene M Johnston	officer: CFO	PO BOX 669047, CHARLOTTE NC 28266
Jonathan Arango	director, officer: President, COO and Secretary	15110 DALLAS PARKWAY, SUITE 600, DALLAS TX 75248
Alex P. Hamilton	director	26 LOOP ROAD, BEDFORD NY 10506